Novavax Stock Performance
| NVAX Stock | USD 7.47 0.17 2.23% |
On a scale of 0 to 100, Novavax holds a performance score of 4. The company secures a Beta (Market Risk) of -0.75, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Novavax are expected to decrease at a much lower rate. During the bear market, Novavax is likely to outperform the market. Please check Novavax's sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Novavax's current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Novavax are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Novavax showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 583.8 M | |
| Total Cashflows From Investing Activities | -204 M |
Novavax Relative Risk vs. Return Landscape
If you would invest 671.00 in Novavax on April 28, 2025 and sell it today you would earn a total of 76.00 from holding Novavax or generate 11.33% return on investment over 90 days. Novavax is currently generating 0.2612% in daily expected returns and assumes 4.3382% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Novavax, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Novavax Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novavax's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novavax, and traders can use it to determine the average amount a Novavax's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0602
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NVAX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.34 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.26 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Novavax is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novavax by adding it to a well-diversified portfolio.
Novavax Fundamentals Growth
Novavax Stock prices reflect investors' perceptions of the future prospects and financial health of Novavax, and Novavax fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novavax Stock performance.
| Return On Equity | -8.98 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.38 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | 734.63 M | ||||
| Shares Outstanding | 161.97 M | ||||
| Price To Earning | (1.36) X | ||||
| Price To Book | 49.52 X | ||||
| Price To Sales | 0.96 X | ||||
| Revenue | 682.16 M | ||||
| EBITDA | (108.04 M) | ||||
| Cash And Equivalents | 1.28 B | ||||
| Cash Per Share | 16.31 X | ||||
| Total Debt | 230.42 M | ||||
| Debt To Equity | 8.24 % | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (87.26 M) | ||||
| Earnings Per Share | 2.75 X | ||||
| Total Asset | 1.56 B | ||||
| Retained Earnings | (5.01 B) | ||||
| Current Asset | 287.26 M | ||||
| Current Liabilities | 76.49 M | ||||
About Novavax Performance
Evaluating Novavax's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Novavax has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novavax has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Novavax operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1541 people.Things to note about Novavax performance evaluation
Checking the ongoing alerts about Novavax for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novavax help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novavax had very high historical volatility over the last 90 days | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 682.16 M. Net Loss for the year was (187.5 M) with profit before overhead, payroll, taxes, and interest of 732.56 M. | |
| Novavax currently holds about 1.28 B in cash with (87.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Novavax has a poor financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors |
- Analyzing Novavax's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novavax's stock is overvalued or undervalued compared to its peers.
- Examining Novavax's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novavax's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novavax's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novavax's stock. These opinions can provide insight into Novavax's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.